Диссертация (1140170), страница 18
Текст из файла (страница 18)
http://www.reutershealth.com/frame2/arch.html.151. O’Brien P and Oyebode F. Psychotropic medication and the heart. //Advances in Psychiatric Treatment. 2003;9:414-423.152. Oberg KC, Bauman JL. QT interval prolongation and torsades de pointesdue to erythromycin lactobionate. Pharmacotherapy 1995;15:687-92.122153.
Ohtani H, Taninaka C, Hanada E, et al. Comparative pharmacodynamicanalysis of QT interval prolongation induced by the macrolides clarithromycin,roxithromycin, and azithromycin. Chemotherapy 2000;44:2630-7.154. Owens Jr, R. and Ambrose, P.
(2002) Torsades de pointes associated withfluoroquinolones. Pharmacotherapy 22: 663-668; discussion 668-672.155. Owens RC Jr. QT prolongation with antimicrobial agents: understandingthe significance. Drugs. 2004;64(10):1091–124.156. Owens RC. Risk Assessment for Antimicrobial Agent-Induced QTcInterval Prolongation and Torsades de Pointes. Pharmacotherapy 2001;21:310-319.157. Paserchia LA, Hewett J, Woosley RL. Effects of ketoconazole on QTc.Clin Pharmacol Ther 1994;55:146.158. Passman R., Kadish A. Polymorphic ventricular tachycardia, long Q-Tsyndrome, and torsades de pointes.
Med Clin North Am 2001 Mar; 85(2): 321-341.159. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P,Smeets HJ, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, andKCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl).2004;82(3):182–8.160. Pickham D., Helfenbein E., Shinn J. A. et al High prevalence of correctedQT interval prolongation in acutely ill patients is associated with mortality: Results ofthe QT in Practice (QTIP) Study Critical Care Medicine 2012;2(40):394-9161. Piquette, R. (1999) Torsade de pointes induced by cisapride/clarithromycininteraction. Ann Pharmacother 33: 22-26.162.
Poluzzi E., Raschi E., Motola D., Moretti U., De Ponti F. Antimicrobialsand the risk of torsades de pointes: the contribution from data mining of the US FDAAdverse Event Reporting System. Drug Saf. 2010 Apr 1;33(4):303-14.163. Priori S.G., Napolitano C., Schwartz P.J. Genetics of cardiac arrhythmias.In Zipes D.P., Libby P., Bonow RO, et al. (eds). Braunwald’s Heart Disease, 7th edn. 2004. - Philadelphia, PA: Elsevier Saunders.
-P. 689-695.123164. Raschi, E., Poluzzi, E., Koci, A., Moretti, U., Sturkenboom, M. and DePonti, F. (2013) Macrolides and torsadogenic risk: emerging issues from the FDAPharmacovigilance Database. J Pharmacovig. DOI: 10.4172/jp.1000104.165. Risk of torsades de pointes with non-cardiac drugs. Editorials. BMJ2000;320:1158-9.166. Roden D.M. Acquired long QT syndromes and the risk of proarrhythmia. J.Cardiovasc. Electrophysiol. 2000; 11 (8): 938–40.167. Roden D.M. Long QT Syndrome. N.
Engl. J. Med. 2008; 358 (2): 169–76.168. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med.2004;350:1013–22.169. Russo V., Puzio G., Siniscalchi N. Azithromycin-induced QT prolongationin elderly patient. Acta Biomed. 2006; 77(1): 30-2.170. Santos N., Oliveira M., Galrinho A., Oliveira J.A., Ferreira L., Ferreira R.QT interval prolongation and extreme bradycardia after a single dose of azithromycin.Rev Port Cardiol. 2010; 29(1): 139-42.171.
Sasich L D FDA Evaluation of Telithromycin (Ketek) April, 26, 2001http://www.healthnet.org/programs/edrug.html.172. Sauer, A. and Newton-Cheh, C. (2012) Clinical and genetic determinantsof torsade de pointes risk. Circulation 125: 1684-1694.173. Schwartz JB. The electrocardiographic QT interval and its prolongation inresponse to medications: differences between men and women. J Gend Specif Med2000;3:25-8.174. Schwartz P.J. Idiopathic long QT syndrome: progress and questions. AmerHeart J 1985; 111: 399-411.175. Schwartz P.J. The congenital long QT syndromes from genotype tophenotype: clinical implications. J.
Intern. Med. 2006; 259 (1): 39–47.176. Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteriafor the long QT syndrome. An update. Circulation. 1993;88:782–4124177. Schwartz P.J., Priori S.G., Spazzolini C. et al. Genotype-phenotypecorrelation in the long-QT syndrome: gene-specific triggers for life-threateningarrhythmias.
Circulation 2001 Jan 2; 103(1): 89-95.178. Schwartz PJ. The Long QT Syndrome. // Vol.7, Futura PublishingCompany, Inc., Armonk, NY, 1997179. Schwartz, P., Stramba-Badiale, M., Crotti, L., Pedrazzini, M., Besana, A.,Bosi, G. et al. (2009) Prevalence of the congenital long-QT syndrome. Circulation 120:1761-1767.180. Sekkarie, M. (1997) Torsades de pointes in two chronic renal failurepatients treated with cisapride and clarithromycin.
Am J Kidney Dis 30: 437-439.181. Selzer A, Wray HW. Quinidine syncope. Paroxysmal ventricularfibrillation occurring during treatment of chronic atrial arrhythmias. Circulation.1964;30:17–26.182. Simkó J., Csilek A., Karászi J., Lorincz I. Proarrhythmic potential ofantimicrobial agents. Infection. 2008 Jun;36(3):194-206.183. Simons FER, Kesselmann MS, Giddings NG, Pelech AN, Simons KJ.Astemizole-induced torsades de pointes.
Lancet 1988;II:624.184. Splawski I., Shen J., Timothy K.W. et al. Spectrum of mutations in longQT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation2000 Sep 5; 102(10): 1178-1185.185. Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F. Death of twosubjects due to imipramine and desipramine metabolite accumulation during chronictherapy: a review of the literature and possible mechanisms. J Forensic Sci1997;42:335-9.186.
Tamargo J. Drug-induced torsade de pointes: from molecular biology tobedside. Jpn J Pharmacol 2000 May; 83(1): 1-19.187. Trinkley K. E. et al. QT interval prolongation and the risk of torsades depointes: essentials for clinicians //Current medical research and opinion. – 2013. – Т.29. – №. 12.
– С. 1719-1726.125188. Tschida SJ, Guay DR, Straka RJ, Hoey LL, Johanning R, Vance-Bryan K.QTc-interval prolongation associated with slow intravenous erythromycin lactobionateinfusions in critically ill patients: a prospective evaluation and review of the literature.Pharmacotherapy 1996;16:663-74.189. Tyson J., Tranebjaerg L., McEntagart M. et al. Mutational spectrum in thecardioauditory syndrome of Jervell and Lange-Nielsen. Hum Genet 2000 Nov; 107(5):499-503.190. van Haarst AD, van't Klooster GA, van Gerven JM, et al.
The influence ofcisapride and clarithromycin on QT intervals in healthy volunteers. Clin PharmacolTher 1998;64:542-6.191. Van Noord C, Eijgelsheim M, Stricker BHC. Drug- and non-drugassociated QT interval prolongation. Br J Clin Pharmacol. 2010;70:16–23.192. Vatta M., Ackerman M.J., Ye B. et al. Mutant caveolin-3 induces persistentlate sodium current and is associated with long-QT syndrome // Circulation. - 2006. Vol. 114. - P. 2104-2112.193.
Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused bynoncardiac drugs. Prog Cardiovasc Dis. 2003;45:415–27.194. Volberg, W., Koci, B., Su, W., Lin, J. and Zhou, J. (2002) Blockade ofhuman cardiac potassium channel human ether-a-go-go-related gene (hERG) bymacrolide antibiotics. J Pharmacol Exp Therapeut 302: 320-327.195. von Keutz E, Schluter G. Preclinical safety evaluation of moxifloxacin, anovel fluoroquinolone.
J Antimicrob Chemother 1999;43(suppl B):91-100196. Wang CP, Guo GB. «Indapamide induced syncope in a patient with longQT syndrome», 2002.197. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade depointes in a patient receiving fluconazole [letter]. Ann Intern Med 1999;131:797.198. Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, et al.Exome sequencing implicates an increased burden of rare potassium channel variants in126the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol.2014;63(14):1430–7.199.
Willman D. How a New Policy Led to Seven Deadly Drugs. Los AngelesTimes December 20, 2000.200. Witchel, H., Hancox, J. and Nutt, D. (2003) Psychotropic drugs, cardiacarrhythmia, and sudden death. J Clin Psychopharmacol 23: 58-77.201. Wolfe SM, et al. New batch of Propulsid deaths and FDA delay. Apr 12,2000 http://www.healthnet.org/programs/edrug.html.202. Woosley R. Drugs that prolong the QTc interval and/or induce torsade depointes; Available from: http://www.crediblemeds.org/everyone/composite-list-allqtdrugs. Cited 3 Mar 2015.203. Woosley RL, Chen Y, Freiman JP, Gilles RA.
Mechanism of thecardiotoxic actions terfenadine. JAMA 1993;269:1532-6.204. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med1996;35:290-1.205. Yong TY, Huang JE, Lau SY, Li JY. «Severe hyponatremia and otherelectrolyte disturbances associated with indapamide», 2011.206. Zareba, W. and Lin, D. (2003) Antipsychotic drugs and QT intervalprolongation.
Psych Q 74: 291-306.207. ZipesDP,WellensHJ.Suddencardiacdeath.Circulation.1998;98(21):2334–51.208. Zuckerman,J.(2004)Macrolidesandketolides:clarithromycin, telithromycin. Infect Dis Clin N Am 18: 621-649.127azithromycin,.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
